Adding plasmapheresis to corticosteroids and alkylating agents: Does it benefit patients with focal segmental glomerulosclerosis?

Nephrology Dialysis Transplantation

Volumn 13, Issue 6, 1998, Pages 1524-1528

  Mitwalli, Ahmed H ^a  

^a KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

Alkylating agents; Corticosteroids; Focal segmental glomerulosclerosis; Plasmapheresis

Indexed keywords

ALKYLATING AGENT; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; PREDNISOLONE; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; FEMALE; FOCAL GLOMERULOSCLEROSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEPHROTIC SYNDROME; ORAL DRUG ADMINISTRATION; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; CHILD; CLINICAL ASSESSMENT; DISEASE CONTROL; DRUG DOSE REDUCTION; FOLLOW UP; HUMAN TISSUE; HYPERTENSION; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LABORATORY TEST; MIDDLE AGED; REMISSION; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE; UROLOGICAL THERAPEUTIC DEVICE;

EID: 0031776296     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/13.6.1524     Document Type: Article

References (34)

1. Banfi G, Morgigi M, Sabadini E, Fellin G, D'Amico G, Ponticelli C. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol 1991; 36(2): 53-59
2. Mendoza SA, Reznik MV, Griswold RW, Krensky MA, Yorgin PD, Tune MB. Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methyprednisolone and alkylating agents. Pediatr Nephrol 1990; 4: 303-307
3. Geary DF, Farine M, Thorner P, Baumal R. Response to cyclophosphamide in steroid-resistant focal segmental glomerulosclerosis: a reappraisal. Clin Nephrol 1984; 22(3): 109-113
4. Tarshish P, Tobin NJ, Bernstein J, Edelmann MC Jr. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. Pediatr Nephrol 1996; 10: 590-593
5. Rich AR. Unrecognized vulnerability of the juxtamedullary glomeruli in lupoid nephrosis. Bull Johns Hopk Hosp 1957; 100: 173
6. Ponticelli C, Rizzoni G, Edeponti A et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993; 43: 1377-1384
7. Mitwalli AH, Al-Wakeel JS, Al Mohaya SS et al. Pattern of glomerular disease in Saudi Arabia. Am J Kidney Dis 1996; 27(6): 797-802
8. Korbet SM, Schwartz MM, Lewis EJ. Primary focal glomerulosclerosis: clinical cause and response to therapy. Am J Kidney Dis 1994; 23: 773-783
9. Tune BM, Kirpekar R, Sibley RK, Reznik VM, Griswold WR, Mendoza SA. Intravenous methylprednisolone and oral alkylating agent therapy for prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up. Clin Nephrol 1995; 43: 84-88
10. Guillot AP, Kim MS. Pulse steroid therapy does not alter the course of focal segmental glomerulosclerosis (Abstract). J Am Soc Nephrol 1993; 4: 276
11. Zimmermann SW. Increased urinary protein excretion in the rat produced by serum from a patient with recurrent focal glomeruloselerosis after renal transplantation. Clin Nephrol 1984; 22 : 32-38
12. Savin VJ, Sharma R, Sharma M et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996; 344(14): 878-83
13. Savin VJ, Artero M, Sharma R, Vincenti F. Risk of recurrence of focal segmental glomerular sclerosis after transplantation can be assessed using an in vitro assay of serum. J Am Soc Nephrol 1993; 4: 125
14. Mowry J, Marik J, Cohen A, et al. Treatment of recurrent focal segmental glomerulosclerosis with high-dose cyclosporine A and plasmapheresis. Transplant Proc 1993; 24(1): 1345-1346
15. Savin VJ. Mechanism of proteinuria in non-inflammatory glomerular diseases. Am J Kidney Dis 1993; 21: 347-362
16. Vincenti F, Biava C, Tomlanovich S et al. Inability of cyclosporine to completely prevent the recurrence of FGS after kidney transplantation. Transplantation 1989; 47: 595-598
17. Walker RG, Kincaid-Smith P. The effect of treatment of corticosteroid-resistant idiopathic (primary) focal and segmental hyalinosis and sclerosis (focal glomerulosclerosis) with cyclosporin. Nephron 1990; 54: 117-121
18. Niaudet P and the French Society of Pediatric Nephrology. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. J Pediatr 1994; 125: 981-986
19. Glassock RJ, Adler SG, Ward HJ, Cohen AH. Primary glomerular diseases. In: Brenner BM, Rector FC ed. The Kidney. 4th edn. Saunders, Philadelphia, 1991; 1233-1238
20. Remuzzi A, Remuzzi G. The effects of nonsteroidal anti-inflammatory drugs on glomerular filtration of protein and their therapeutic utility. Semin Nephrol 1995; 15(3): 236-243
21. Gansevoort RT, de Zeeuw D, de Jong PE. Additive antiproteinuric effect of ACE inhibition and low-protein diet in human renal disease. Nephrol Dial Transplant 1995; 10(4): 497-504
22. Hoyer JR, Vernier RL, Najarian JS, Raij L, Simmons RL, Michael AF. Recurrence of idiopathic nephrotic syndrome after renal transplantation. Lancet 1972; 2: 343-348
23. Pinto J, Lacerda G, Cameron JS, Turner DR, Bewick M, Ogg CS. Recurrence of FSGS in renal allografts. Transplantation 1981; 32: 83-89
24. Leumann EP, Donckerawolcke RAM, Kuijten R, Largiader F. Recurrence of FSGC in the transplanted kidney. Nephron 1980; 25: 65-71
25. Cameron JS, Senguttuvan P, Hartley B et al. Focal segmental glomerulosclerosis in fifty nine renal allografts from a single centre: analysis of risk factors for recurrence. Transplant Proc 1989; 21: 2117-2118
26. Senggutuvan P, Cameron JS, Hartley RB et al. Recurrence of focal segmental glomeruloscierosis in transplanted kidneys: analysis of incidence and risk factors in 59 allografts. Pediatr Nephrol 1990; 4: 21-28
27. Dantal J, Baatard R, Hourmant M, Cantarovich D, Buzelin F, Soulillou JP. Recurrent nephrotic syndrome following renal transplantation in patients with FGS: a one-center study of plasma exchange effects. Transplantation 1991; 52: 827-831
28. Cochat P, Kassir A, Colon S et al. Recurrent nephrotic syndrome after transplantation: early treatment with plasmapheresis and cyclophosphamide. Pediatr Nephrol 1993; 7: 50-54
29. Laufer J, Ettenger RB, Ho WG, Cohen AH, Merick JL, Fine RN. Plasma exchange for recurrent nephrotic syndrome following renal transplantation. Transplantation 1988; 46: 1540-1542
30. Artero ML, Sharma R, Savin VJ, Vincenti F. Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis 1994; 23(4): 574-581
31. Tojo K, Sakai S, Miyahara T. Therapeutic trial of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS). Prog Clin Biol Res 1990; 337: 193-194
32. Dantal J, Bigot E, Bogers W et al. Effect of plasma protein absorption on protein excretion in kidney-transplant recipients with nephrotic syndrome. N Engl J Med 1994; 330: 7-14
33. Munoz J, Sanchez M, Perez-Garcia R, Anaya F, Valderrabano F. Recurrent focal glomerulosclerosis in renal transplants. Proteinuria relapsing following plasma exchange. Clin Nephrol 1985; 24: 213-214
34. Euler HH, Schroeder JO. Plasmapheresis for lupus nephritis. N Engl J Med 1992; 327(14): 1028-1030